-
Sharing economy promotes the efficient development of Chinese medicine industry
Time of Update: 2021-12-05
With the gradual development of the two pilot provinces of the National Medical Community and the 567 compact county medical community construction pilot projects , To ensure the same quality and same price of regional TCM decoction pieces, and improve the TCM service capabilities of primary medical institutions .
-
The development prospects of the biopharmaceutical market are promising, and a large number of pharmaceutical companies are spending huge sums of money to deploy
Time of Update: 2021-12-05
However, in recent years, with the expiration of patents for some original research drugs and the continuous expansion of the biopharmaceutical market, many pharmaceutical companies in China have accelerated their deployment in the biopharmaceutical field .
-
The cold wave has exceeded the standard by a large margin!
Time of Update: 2021-12-05
In recent years, under the influence of multiple factors such as continuous increase in policies, capital entry, and the influx of talents, China's biomedical industry has developed rapidly and accelerated the pace of innovation and upgrading.
-
The development of Chinese medicine injection industry is limited, and the transformation to modernization is imminent
Time of Update: 2021-12-05
In this context, the industry predicts that as the country pays more and more attention to safety issues, the policy of restricting the clinical use of Chinese medicine injections will become tighter, and some companies’ products or certain varieties will be eliminated at an accelerated rate.
-
The Korean pharmaceutical company Rituximab accounts for 40% of the European market. What is the current status of domestic production?
Time of Update: 2021-12-05
Image source: Fosun Pharma AnnouncementAs the first rituximab biosimilar drug approved for marketing in China, Han Likang has a domestic sales of 2.
-
Novartis' generic drug unit Sandoz may sell for US$21.6 billion
Time of Update: 2021-12-05
According to reports, Thomas and Andreas of the Struengmann family sold the generic drug company Hexal to Novartis in 2005, and the company has also become part of Sandoz .
-
The IPO preparation team on the Sci-tech Innovation Board welcomes a pharmaceutical company again, and has repeatedly broken through the barriers
Time of Update: 2021-12-05
The prospectus shows that Baili Tianheng Pharmaceutical chose the fourth set of criteria for the Sci-tech Innovation Board for this IPO: the estimated market value is not less than RMB 3 billion, and the operating income in the most recent year is not less than RMB 300 million .
-
Ascent Pharmaceuticals Orebatinib Receives EU Orphan Drug Qualification Certification
Time of Update: 2021-12-05
Although the first and second generation drugs BCR-ABL TKI have significant clinical benefits for the treatment of CML, acquired drug resistance has always been the main challenge for the treatment of CML .
-
This year, more than one billion yuan API projects have started construction
Time of Update: 2021-12-05
After the third phase of the project is fully completed, it is expected to achieve an annual output value of about 12 billion yuan .
-
The high-prosperity domestic substitution of the pharmaceutical industry boosts the pharmaceutical machinery industry to usher in a new round of growth
Time of Update: 2021-12-05
For many companies' performance increase, the analysis believes that this is mainly due to the high prosperity of the downstream pharmaceutical market and the continuous acceleration of domestic substitution .
-
Forecast of the seventh batch of centralized procurement of anti-tumor drugs! Who are you most looking forward to for the 10 varieties in the over 4 billion market?
Time of Update: 2021-12-05
com shows that in 2020, the terminal sales of anti-tumor drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) will exceed 100 billion yuan, an increase of 10.
-
To speed up the "going global" of the Chinese medicine industry, efforts must be made from three aspects at the same time
Time of Update: 2021-12-05
It is reported that Guangxi has been vigorously advancing the development of the Chinese medicine industry in recent years and has continuously accelerated the pace of "going global .
-
Hengrui put down his "prudence" and was forced to use two "big tricks" in a row
Time of Update: 2021-12-05
After revenue exceeds 10 billion, it can still maintain an ultra-high growth rate of about 30%, which eventually prompted Hengrui to choose What are the reasons for the capitalization of R&D investment?It is true that with the increase in Hengrui’s base, the pressure on corporate growth has doubled.
-
The 9th Biological Fermentation Exhibition in 2022, "March in Spring, Happy Gathering in Jinan" Fermentation Covenant is waiting for you
Time of Update: 2021-12-05
2022 The 9th Biological Fermentation Products and Technology Equipment Exhibition (Jinan) and Biological Industry Series Exhibition will be held in Shandong International Convention and Exhibition Center (No.
-
Under the general trend of innovation, how should pharmaceutical companies break the bottleneck of transformation?
Time of Update: 2021-12-05
It is reported that the current leading traditional pharmaceutical companies such as CSPC, Kelun, and Chia Tai Tianqing are all planning to transform the research and development of innovative drugs and high-end generic drugs, and they are accelerating .
-
In order to focus on asset optimization, this pharmaceutical company plans to continue to sell non-core businesses for 1 billion yuan
Time of Update: 2021-12-05
In 2015, Renfu Pharmaceutical issued an asset announcement, announcing the formation of a consortium with Junzheng Group and Junzheng Chemical, and proposed to transfer the shares of Huatai Insurance listed on the Beijing Stock Exchange, and said that the investment would be beneficial to its construction of medical service projects that integrate medical care and care.
-
The domestic pharmaceutical R&D expenditure is expected to reach 49.6 billion US dollars in 2025, and the innovation environment will usher in a huge change
Time of Update: 2021-12-05
Nowadays, many companies have poured in and continue to promote drug innovation and research and development .
After years of hard work, China's biopharmaceutical industry has undergone significant changes, from the past generic drug-based pharmaceutical industry to innovative research and development.
-
Small molecule drug research and development is still the main battlefield for new drug research and development
Time of Update: 2021-12-05
[Information search] [Add to Favorites] [Tell friends] [Print this article] [Close window] Similar information js?cdnversion='+~(-new Date()/36e5)]; Keywords: Small molecule drug research and development is still the main battlefield of new drug research and development, small molecule drugs Next: After entering centralized procurement and medical insurance, transnational drugs How is the sales performance of the company's products?
-
A batch of pharmaceutical companies' 2021 annual performance forecasts have been released!
Time of Update: 2021-12-05
The four pharmaceutical companies that have anticipated net profit growth in 2021 include Yan'an Bikang, Hualan, and Zuoli Pharmaceuticals.
61%; in 2021, the net profit attributable to the owners of the parent company is expected to be approximately 197 million to 266 million yuan, an increase of approximately 141.
-
In order to accelerate the development of new drugs, domestic pharmaceutical companies are constantly accelerating the pace of foreign cooperation
Time of Update: 2021-12-05
In addition to Hengrui, on November 11, Jichuan Pharmaceutical also issued an announcement, announcing that it has reached a strategic cooperation in product development, production and commercialization with Tianjing Bio on long-acting recombinant human growth hormone (Yitan) .
